MarketCap
Adamis Pharmaceuticals Corporation ADMP
Facebook
X
Telegram
Adamis Pharmaceuticals Corporation Total Current Liabilities | ADMP
Annual Total Current Liabilities Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.4 M | 11.2 M | 19.9 M | 9.41 M | 11.6 M | 8.79 M | 8.61 M | 2.75 M | 3.39 M | 4.68 M | 2.89 M | 3.11 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.9 M | 2.75 M | 8.14 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M |  USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Organogenesis Holdings
ORGO
|
100 M | $ 0.84 | 0.19 % | $ 106 M | USA |
 |
Evoke Pharma
EVOK
|
10.4 M | - | - | $ 36.6 M | USA |
 |
Pacira BioSciences
PCRX
|
121 M | $ 36.43 | 0.03 % | $ 1.62 B | USA |
 |
Perrigo Company plc
PRGO
|
1.01 B | $ 15.83 | 0.83 % | $ 2.19 B | USA |
 |
Rockwell Medical
RMTI
|
9.58 M | $ 7.76 | 2.04 % | $ 279 M | USA |
 |
Solid Biosciences
SLDB
|
33.5 M | $ 6.65 | 7.52 % | $ 582 M | USA |
 |
Tilray
TLRY
|
358 M | $ 2.91 | 3.56 % | $ 325 M |  Canada |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
Veru
VERU
|
7.79 M | $ 2.14 | 3.88 % | $ 31.3 M | USA |
 |
Viatris
VTRS
|
7.09 B | $ 19.72 | 5.03 % | $ 22.9 B | USA |
 |
cbdMD
YCBD
|
3.19 M | $ 0.42 | 6.96 % | $ 1.69 M | USA |
 |
China Pharma Holdings
CPHI
|
7.4 M | $ 0.57 | 8.66 % | $ 2.45 M |  China |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
DURECT Corporation
DRRX
|
7.71 M | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
OptiNose
OPTN
|
163 M | - | - | $ 1.08 B | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
Canopy Growth Corporation
CGC
|
158 M | $ 0.65 | -3.6 % | $ 194 M | Canada |
 |
Harrow Health
HROW
|
96.3 M | $ 26.86 | 3.15 % | $ 987 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
36.7 M | $ 5.26 | 4.99 % | $ 78.1 M | USA |
 |
Relmada Therapeutics
RLMD
|
6.43 M | $ 3.92 | 3.98 % | $ 155 M | USA |
 |
Emergent BioSolutions
EBS
|
132 M | $ 6.04 | 3.25 % | $ 323 M | USA |
 |
Cronos Group
CRON
|
48.2 M | $ 3.62 | -2.82 % | $ 1.39 B | Canada |
 |
Evolus
EOLS
|
75.3 M | $ 6.86 | 0.88 % | $ 442 M | USA |
 |
Bausch Health Companies
BHC
|
4.18 B | $ 8.19 | 2.7 % | $ 3.04 B | Canada |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 3.51 | 6.21 % | $ 175 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.83 M | $ 1.12 | 5.1 % | $ 1.89 M | USA |
 |
TherapeuticsMD
TXMD
|
4.78 M | $ 1.7 | -0.58 % | $ 19.7 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
128 M | - | - | $ 150 M | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
53.1 M | - | - | $ 5.07 M | USA |